Incidence of ventilator-associated pneumonia: Egyptian study

被引:8
|
作者
Elkolaly, Reham M. [1 ]
Bahr, Hoda M. [1 ]
El-Shafey, Basem, I [1 ]
Basuoni, Ahmed S. [2 ]
Elber, Eman H. [3 ]
机构
[1] Tanta Univ, Fac Med, Chest Dept, Tanta, Egypt
[2] Tanta Univ, Fac Med, Anaesthia Dept, Tanta, Egypt
[3] Tanta Univ Hosp, Chest Dept, Tanta, Egypt
关键词
hospital acquired pneumonia; intensive care unit; mechanical ventilation; ventilator-associated pneumonia; INTENSIVE-CARE-UNIT; RISK-FACTORS; SUSCEPTIBILITY; ETIOLOGY; ONSET;
D O I
10.4103/ejb.ejb_43_18
中图分类号
R56 [呼吸系及胸部疾病];
学科分类号
摘要
Background Despite different ICU admission causes, ventilator-associated pneumonia (VAP) is still a common cause of mortality and morbidity in intubated patients and impedes obvious progression in diagnostic modalities and management of these infections. Aim of study The aim of this study was to estimate VAP incidence in Tanta University Hospitals ICUs. Settings and design This was a crossover observational study. Patients and methods This was a one-year study (April 2015 to March 2016), including patients on invasive ventilation who developed VAP, with evaluation of admission and ventilation causes, isolation of causative organisms, and study of used antibiotics and ventilation modes. Statistical analysis Data were statistically analyzed using the SPSS software for Windows (IBM SPSS Statistics 21.0). Results It is a statistics based study aimed to trace infection incidence in national hospital ICUs. Among 222 admitted patients, only 38.4% fulfilled the criteria of VAP. Admission was because of cardiovascular impairment, cardiac arrest, respiratory failure, or head trauma. The ventilation mode at VAP time was assisted control (75%) and synchronized intermittent mandatory ventilation (25%). The minimum intubation period was 7 days, whereas the maximum period was 37 days. Isolated organisms were Pseudomonas (37.5%), Klebsiella (25%), Staphylococcus (20.8%), and methicillin-resistant Staphylococcus aureus (4.2%). The antibiotics used were amikacin, imipenem, vancomycin, levofloxacin, ceftazidime, and teicoplanin (29, 25, 21, 12.5, 8.3, and 4.2%, respectively). The minimum period of antibiotic used was 5 days, whereas the maximum period was 35 days. The highest incidence of VAP occurred in February, whereas the lowest incidence occurred in July. Conclusion The incidence of VAP is still high and varies according to the intubation cause and period, and the underlying morbidity. More efforts must be made to prevent, diagnose, and manage infection early and properly to reduce patient suffering and to reduce the burden on the serving hospitals.
引用
收藏
页码:258 / 266
页数:9
相关论文
共 50 条
  • [1] Incidence of ventilator-associated pneumonia: Egyptian study
    Reham M. Elkolaly
    Hoda M. Bahr
    Basem I. El-Shafey
    Ahmed S. Basuoni
    Eman H. Elber
    Egyptian Journal of Bronchology, 2019, 13 : 258 - 266
  • [2] The Incidence of Ventilator-Associated Tracheobronchitis and its Relationship to Ventilator-Associated Pneumonia
    Ninan, N.
    Esan, A.
    Wentowski, C.
    Abdelwahed, A.
    Sung, A.
    George, L.
    AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE, 2010, 181
  • [3] Incidence of Ventilator-Associated Pneumonia compared to Ventilator-Associated Events in the ED
    Yang, Laurel
    Sabb, Dylan
    Munzer, Brendan
    Gonzaga, Jessica
    Grall, Kristi
    Denninghoff, Kurt
    Stoneking, Lisa
    DeLuca, Lawrence
    CRITICAL CARE MEDICINE, 2013, 41 (12)
  • [4] Adherence to Ventilator-Associated Pneumonia Bundle and Incidence of Ventilator-Associated Pneumonia in the Surgical Intensive Care Unit
    Bird, Dorothy
    Zambuto, Amanda
    O'Donnell, Charles
    Silva, Julie
    Korn, Cathy
    Burke, Robert
    Burke, Peter
    Agarwal, Suresh
    ARCHIVES OF SURGERY, 2010, 145 (05) : 465 - 470
  • [5] Incidence and outcome of polymicrobial ventilator-associated pneumonia
    Combes, A
    Figliolini, C
    Trouillet, JL
    Kassis, T
    Wolff, M
    Gibert, C
    Chastre, J
    CHEST, 2002, 121 (05) : 1618 - 1623
  • [6] Incidence and outcome of ventilator-associated pneumonia: an audit
    Jha, R.
    Carrick, M. A.
    Winson, D.
    Gratrix, A.
    ANAESTHESIA, 2012, 67 : 14 - 14
  • [7] Ventilator-Associated Tracheobronchitis and Ventilator-Associated Pneumonia
    Kollef, Marin H.
    CHEST, 2013, 144 (01) : 3 - 5
  • [8] An Observational Veneto Research on Ventilator-Associated Pneumonia (OVeRVAP): attributable mortality and cumulative incidence of ventilator-associated pneumonia
    Olivieri, Armando
    Del Monte, Daniele
    Benacchio, Luca
    Bonvicini, Daniele
    Baiocchi, Marco
    Allegri, Camilla
    Fornasier, Luana
    Carlot, Alessandra
    Psimadas, Ioannis
    Bonato, Alfeo
    Bernasconi, Mara
    Mede, Andrea
    Bianchin, Andrea
    Peta, Mario
    Caravello, Massimiliano
    Rampazzo, Roberta
    Pedrini, Antonella
    Dalsasso, Massimiliano
    Saggioro, Debora
    Zennaro, Andrea
    Ori, Carlo
    Pizzirani, Ernesto
    MINERVA ANESTESIOLOGICA, 2018, 84 (07) : 811 - 819
  • [9] From ventilator-associated tracheobronchitis to ventilator-associated pneumonia
    Martin-Loeches, I.
    Nseir, S.
    Valles, J.
    Artigas, A.
    REANIMATION, 2013, 22 (03): : 231 - 237
  • [10] Prevention of Ventilator-Associated Pneumonia and Ventilator-Associated Conditions
    Mishra, Shakti Bedanta
    Azim, Afzal
    Muzzafar, Syed Nabeel
    CRITICAL CARE MEDICINE, 2015, 43 (11) : E527 - E528